申请人:Theravance, Inc.
公开号:US07989484B2
公开(公告)日:2011-08-02
The invention relates to compounds having the formula:
wherein: Q, W, Y, Z, r, and Ar are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
本发明涉及具有以下式子的化合物:其中:Q,W,Y,Z,r和Ar如规范中所定义,并且其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和神经肽酶抑制活性。本发明还涉及包含这些化合物的制药组合物,使用这些化合物的方法以及制备这些化合物的过程和中间体。